The sources behind what we say
about PCOS across midlife.

PCOS is a lifelong condition affecting metabolic, reproductive, dermatological and psychological health, with symptoms and risks that evolve across the lifespan — including through perimenopause and postmenopause. Care should not stop after the fertility years.

The single most-citable document on modern PCOS care. Bring the section on midlife metabolic and cardiovascular screening.

Women with PCOS enter menopause with a higher androgen baseline and lose ovarian androgens more slowly than women without PCOS, so hirsutism, androgenetic hair loss and acne often persist or worsen around the final menstrual period.

The mechanistic answer to 'why is my chin hair getting worse at 52?'. Not a personal failure, a documented trajectory.

Women with PCOS carry a higher lifetime risk of type 2 diabetes, non-alcoholic fatty liver disease (MASLD), hypertension and cardiovascular disease — and the risk gap widens across midlife rather than narrowing.

The evidence base for asking for a full metabolic panel (fasting glucose, HbA1c, lipids, liver enzymes, BP) rather than 'you look fine' at your midlife physical.

Resistance training two to three times a week improves insulin sensitivity, body composition and androgen markers in women with PCOS — with effect sizes comparable to metformin in some trials.

Muscle is the biggest glucose-disposal site you have. The strength-training half is the one most consistently under-prescribed.

GLP-1 receptor agonists (semaglutide, liraglutide) improve weight, insulin sensitivity and menstrual regularity in women with PCOS; the evidence is growing quickly but not yet in formal guideline recommendations.

Useful for the 'my doctor said GLP-1s aren't for PCOS' conversation. They are being used off-label with growing evidence; the guideline update is expected to catch up.

Metformin remains a first-line pharmacological option for the metabolic features of PCOS in adults, with evidence supporting continued use through midlife where indicated.

Named here because women with PCOS are still routinely told to stop metformin 'now you're not trying to conceive'. The guideline is explicit that metabolic indications continue.

Women with PCOS have roughly two- to four-fold higher risk of endometrial cancer than women without PCOS, driven by chronic unopposed estrogen exposure from anovulation, plus higher rates of obesity, insulin resistance and type 2 diabetes.

The evidence base for taking heavy or prolonged bleeding — or bleeding after a long gap — seriously in PCOS. Not to alarm; to act early.

Any bleeding 12 months or more after the final menstrual period requires prompt gynecological assessment (endometrial thickness on transvaginal ultrasound, and biopsy where indicated).

Applies to everyone, but named here because PCOS women arrive with a higher baseline endometrial risk. Do not wait it out.

Transdermal estrogen (patch, gel or spray) does not raise sex hormone binding globulin or triglycerides and carries a lower thrombotic risk than oral estrogen, making it generally preferred in women with metabolic risk factors — including PCOS.

The core reference behind the 'transdermal-first in PCOS' framing you now see in menopause-society guidance.

In women with a uterus taking systemic estrogen, adequate endometrial protection with a progestogen (micronised progesterone, or a levonorgestrel-releasing intrauterine system) is required to prevent endometrial hyperplasia and cancer.

Particularly relevant in PCOS given the higher baseline endometrial risk. A Mirena IUS covers contraception and endometrial protection in one device.

Depression and anxiety are significantly more common in women with PCOS than in the general population across all life stages, and international guidelines recommend routine screening at every PCOS review.

Obstructive sleep apnea is substantially more prevalent in women with PCOS (roughly 5–10× higher than BMI-matched controls in some series), and untreated OSA worsens insulin resistance, blood pressure and mood.

If a partner reports snoring, or you wake unrefreshed, ask for a sleep study. Do not accept 'that's just perimenopause'.

ADHD is meaningfully over-represented in women with PCOS, with shared dopaminergic and androgen-signalling pathways proposed as one biological substrate.

In perimenopause the estrogen drop often unmasks ADHD that was previously compensated. Naming the overlap changes the appointment.